Carfilzomib (Kyprolis) falls under anti-cancer medication, which acts as a selective PI (Proteasome Inhibitor). Chemically, this agent basically is a tetrapeptide epoxyketone and an analog of the epoxomicin.
It is derived from the epoxomicin, a natural product that was demonstrated by the laboratory of Craig Crews at Yale University in order to inhibit the proteasome.
The laboratory of Crews subsequently originated a more specific derivative of the epoxomicin known as YU101, was licensed to Proteolix, Inc.
Scientists at the Proteolix originated a new and distinct compound that had potential use as a medication in humans, named carfilzomib.
Certain clinical trials for carfilzomib injection continue under Onyx Pharma, which acquired Proteolix in the year of 2009.
In the month of January, 2011, the Food and Drug Administration granted fast-track status to carfilzomib, enabling Onyx in order to start the rolling submission of application of its new drug for the carfilzomib.
In the month of December 2011, the Food and Drug Administration granted Onyx standard review designation, for its new drug application submission based on the 003-A1 study, an open-label, single-arm phase IIb trial.
The trial assessed 266 heavily-pretreated patients with RRMM (Relapsed/Refractory Multiple Myeloma) who had taken at least 2 prior therapies, including bortezomib and either lenalidomide or thalidomide.
The carfilzomib price is around 47,325 INR for a supply of vial of single injection, depending on the pharmacy/wholesaler you visit. Any WHO-GDP & ISO certified pharmaceutical wholesaler company would be best to buy carfilzomib.carf
